Candel Therapeutics, Inc.
CADL· Nasdaq
Released Aug 13, 2024, before the open
10-Q filed Aug 13, 2024, 44 days after period end · 0000950170-24-095784
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | — | — | $31.00K | $31.00K |
| Net Income | -$22.24M | -$9.61M | -$4.15M | -$17.08M |
| EPS Diluted |
Candel Therapeutics, Inc. · CIK 1841387 · Engraved from SEC EDGAR
| -$0.74 |
| -$0.33 |
| -$0.14 |
| -$1.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.